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Heat-shock protein 90a in plasma
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Abstract
Heat-shock proteins (HSPs) are evolutionarily conserved proteins with important cellular homeostasis functions during
harmful conditions, including inflammation. Some HSPs are secreted extracellularly and act on distant cells by down-
regulating inflammation and increasing cellular stress defence mechanisms. HSP90a has been postulated to signal
fatigue in chronic inflammation. We investigated whether HSP90a is associated with fatigue in patients with Crohn’s
disease. Fifty-three patients with newly diagnosed Crohn’s disease were included in a cross-sectional study. Data on
demographics and disease distribution were obtained. Fatigue was measured by the fatigue visual analogue scale (fVAS).
Disease activity was assessed by the Simple Endoscopic Score for Crohn’s disease and Harvey Bradshaw Index.
C-reactive protein, faecal calprotectin and HSP90a were also measured. The median fVAS score was 52 mm, indicating
significant fatigue. HSP90a scores correlated significantly with fVAS (r¼ 0.31, P¼ 0.03). In a multivariate regression
model, HSP90a was the only significant contributor to fVAS scores (b¼ 0.31, P¼ 0.03). When patients were dicho-
tomised into groups with high and low HSP90a concentrations, significantly higher fVAS scores were demonstrated in
the group with high HSP90a (M¼ 62.4, confidence interval 53.0–71.8 vs. 43.3, 31.6–55.0; P¼ 0.01). Thus, HSP90a may
contribute to fatigue generation and/or modulation in patients with Crohn’s disease.
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Introduction
Fatigue can be defined as ‘an overwhelming sense of
tiredness, feeling of exhaustion, and a lack of energy’1
and has been recognised as a common and substantial
complaint in many chronic inflammatory conditions,
including rheumatoid arthritis, primary Sj€ogren’s syn-
drome, primary sclerosing cholangitis and inflammato-
ry bowel diseases (IBDs).2,3 Fatigue reduces quality of
life, can be so severe that it leads to social withdrawal
and/or inability to work and is sometimes debilitating.
The mechanisms that lead to and modulate fatigue
are mostly unknown. Depressive mood, psychosocial
factors and pain influence fatigue, but growing
evidence indicates that inflammation and/or different
cellular stress conditions trigger neuro-immune mecha-
nisms involved in the generation of fatigue.4,5 A pre-
vailing hypothesis is that fatigue is part of an
evolutionarily conserved protective mechanism
(‘sickness behaviour’) activated in animals and
humans during infection or inflammation in order to
increase their ability to survive. Fatigue constitutes a
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substantial part of this behaviour, which also includes
sleepiness, lack of thirst and appetite, depressive mood
and social withdrawal.6
IL-1b is an important molecule in the generation of
sickness behaviour, and thus fatigue, in both animals
and humans.7,8 IL-1b is produced by activated innate
immune cells during inflammation and is actively
transported to the brain, where it binds to specific
receptors.9 IL-1b inhibition reduces fatigue, indicating
its importance in fatigue signaling.10
Heat-shock proteins (HSPs) are highly conserved
proteins classified according to their molecular
weight. They have important cell-protective functions,
acting as intracellular chaperones in protein trafficking
and folding.11 Some HSPs are secreted extracellularly
and may influence distant cells, such as innate immune
cells and neurons.12 Production of HSPs is triggered by
different types of cellular stress, such as inflammation,
pathogens, thermal stress and oxidants. HSP90 consists
mainly of two isoforms: the inducible HSP90a and con-
stitutively expressed HSP90b.13 During inflammation
and other forms of cellular stress, HSP90a is secreted
extracellularly. We previously showed that a high
concentration of HSP90a in the blood is associated
with severe fatigue in patients with primary Sj€ogren’s
syndrome,4 and we have postulated that peripherally
produced HSP90a passes the blood–brain barrier and
binds to TLR4 on microglia. This leads to intracerebral
production of IL-1b, which induces fatigue.
Crohn’s disease is a chronic IBD that can affect any
part of the gastrointestinal tract from the oral orifice to
the anus but most frequently involves the ileocolon.14
Clinically significant fatigue is reported in 40–80% of
patients with Crohn’s disease and constitutes a sub-
stantial problem.3
The aim of the current study was to investigate
whether this association between HSP90a and fatigue
is evident in patients with newly diagnosed and
untreated Crohn’s disease.
Materials and methods
A total of 53 patients with newly diagnosed and
untreated Crohn’s disease at the Unit of
Gastroenterology, Stavanger University Hospital,
were consecutively included in a cross-sectional study
and underwent one study visit between 1 January
2013 and 31 December 2016. Descriptive data are
given in Table 1. Inclusion criteria were age 16 yr
and newly diagnosed Crohn’s disease based on
clinical, laboratory, endoscopic, histological and radio-
logical criteria according to European Crohn’s and
Colitis Organisation (ECCO) guidelines. Exclusion cri-
teria were a history of previous IBD or pregnancy.
All patients were recruited at the time of endoscopy,
with all study data collected within 3 d after
colonoscopy.
Assessment of fatigue
The fatigue visual analogue scale (fVAS), a generic and
unidimensional fatigue instrument, was used to rate the
severity of fatigue. The fVAS comprises a 100 mm hor-
izontal line with vertical anchors. The wording on the
left end (0 mm) was ‘no fatigue’ and on the right end
(100 mm) was ‘fatigue as bad as it can be’. The fVAS is
a frequently used and widely accepted fatigue instru-
ment, and clinically important fatigue has been defined
as an fVAS score 50.3
Assessment of disease activity
Harvey Bradshaw Index. Disease activity was rated using
the Harvey Bradshaw Index (HBI). This index is based
on patient symptoms and includes general well-being,
abdominal pain and number of loose stools the previ-
ous day, in addition to the presence of a palpable mass
in the abdomen and extra-intestinal manifestations,
such as arthralgia, fistula and abscesses.15
Simple Endoscopic Score for Crohn’s Disease. For optimal
objective rating of disease activity, we used the Simple
Endoscopic Score for Crohn’s Disease (SES-CD) to
grade intestinal inflammation.16
Inflammatory markers. Serum C-reactive protein (CRP)
measured at the time of endoscopy ( 3d.) and
faecal calprotectin (from 4 wk before until 3 d after
endoscopy) were measured in all patients.
Table 1. Selected demographic and clinical characteristics of 53
patients with newly diagnosed Crohn’s disease.
Variable
Age (yr) 35 (16–78)
Males, n (%) 23 (43.4)
Disease distribution, n (%)
Ileal 28 (53.8)
Colonic 3 (5.8)
Ileocolonic 21 (40.4)
fVAS (mm) 52 (1–100)
HSP90a (ng/ml) 17.2 (6.4–55.1)
HBI 5 (0–14)
CRP (mg/l) 9.8 (1–139)
Faecal calprotectin (mg/kg), n¼ 47 254 (15–4432)
SES-CD 7 (1–37)
Haemoglobin (g/dl), M (SD) 13.4 (1.6)
Ferritin (mg/l) 84 (7–1382)
Data are presented as the median (range) unless otherwise noted.
fVAS: fatigue visual analogue scale; HSP: heat-shock protein HBI: Harvey
Bradshaw Index; CRP: C-reactive protein; SES-CD: Simple Endoscopic
Score for Crohn’s Disease.
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Markers of anaemia and iron deficiency
Haemoglobin and ferritin were measured in all patients
at the time of endoscopy ( 3d.).
HSP90a analysis
At the time of inclusion, blood samples were drawn
into EDTA tubes from all patients. These samples
were kept cold on ice before centrifuging at 2400 g
for 10 min at 4C. Plasma was immediately separated,
aliquoted and stored at 80C until analysis.
HSP90a was measured in duplicate using a commer-
cially available ELISA kit (Enzo Life Sciences,
Farmingdale, NY). Samples were diluted 1:25 and ana-
lysed following the manufacturer’s protocol. The final
absorbance was read at 450 nm using a Synergy H1
plate reader (BioTek, Bad Friedrichshall, Germany).
The HSP90a concentration was determined using
a standard curve generated from calibrating solutions
of known concentrations. According to the
manufacturer, the detection range of the method is
0.0625–4 ng/mL, with a sensitivity of 50 pg/ml and
no cross-reactivity with HSP90b. The calculated coef-
ficient of variance (CV) between duplicates was < 13%,
and the inter-assay CV was < 8%.
Statistical analysis
The normality of the data was tested using the
Shapiro–Wilk test. Correlations were analysed by
Spearman’s rank correlation test. Differences between
two independent groups were analysed using the
independent-samples t-test. Univariable linear regres-
sion models were explored using fVAS scores as the
dependent variable and HSP90a, SES-CD, CRP, hae-
moglobin, ferritin, age and sex as independent variables.
Multivariable analyses were performed first in a
preliminary model including all variables used in uni-
variable analysis. Then, we selected five independent
variables (HSP90a, SES-CD, CRP, age and sex), and
finally a backwards stepwise model selection was used
to exclude non-significant independent variables. A sig-
nificance level of 0.05 was used. As this was an explor-
atory study, no power-estimation was performed.
Data are available from the author upon reason-
able request.
Ethical considerations
This study was approved by the Norwegian regional
ethics committee (REK 2011/2631) and was carried
out in compliance with the principles outlined in the
Declaration of Helsinki. All patients provided written
informed consent to participate in the study. The study
was registered at ClinicalTrials.gov (NCT01551563).
Results
Baseline characteristics
The majority of patients (53.8%) had ileal disease dis-
tribution. The median (range) HBI and SES-CD
were 5 (0–14) and 7 (1–37), respectively, which indicate
mild to moderate disease activity at the time of diag-
nosis. The median (range) fVAS score was 52mm
(1–100mm), whereas the median HSP90a concentra-
tion was 17.2 ng/ml (6.4–55.1 ng/ml). Faecal calprotec-
tin data were missing for six subjects. Baseline data are
given in Table 1.
HSP90a and fatigue
HSP90a significantly positively correlated with fVAS
scores (r¼ 0.31, P¼ 0.03).
Regression models
In the univariable regression analysis, when using fVAS
scores as the dependent variable, there was a modest
but significant positive association with HSP90a
(r2¼ 0.09, P¼ 0.03). In addition, CRP was significantly
and positively associated with fVAS scores in the
univariable models, whereas SES-CD, haemoglobin,
ferritin, age and sex were not (Table 2).
In a preliminary multivariable linear regression
model, all independent variables from univariable anal-
yses were included. Assuming a target r2 of 0.2, a power
of 0.8 and a significance level of 0.05, a maximum
number of five independent variables could be included
in the model based on 53 cases available for calcula-
tion.17 We chose to include HSP90a, CRP, SES-CD,
age and sex. In this model, r2 was 0.20, P¼ 0.06, and
only HSP90a was a significant contributor to fVAS
scores (b¼ 0.35, P¼ 0.04; Table 3). Stepwise backward
model selection was then applied to exclude non-
Table 2. Univariable linear regression analysis in 53 patients
with Crohn’s disease using fVAS scores as the depen-
dent variable.
fVAS
b P value
Age 0.19 0.17
Sex 0.17 0.21
CRP (mg/l) 0.29 0.04
SES-CD 0.20 0.15
Haemoglobin (g/dl) -0.08 0.57
Ferritin (mg/l) 0.15 0.27
HSP90a (ng/ml) 0.31 0.03
fVAS: fatigue visual analogue scale; HSP: heat-shock protein HBI: Harvey
Bradshaw Index; CRP: C-reactive protein; SES-CD: Simple Endoscopic
Score for Crohn’s Disease.
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significant independent variables. Ultimately, HSP90a
was shown to influence fVAS the most
(b¼ 0.31, P¼ 0.03).
When selecting the 20 patients with the highest
HSP90a concentrations versus the 20 patients with
the lowest HSP90a concentrations (21.9–55.1 ng/ml
vs. 6.4–13.9 ng/ml), fVAS scores were significantly
higher in the high HSP90a group (M¼ 62.4, confidence
interval (CI) 53.0–71.8) compared to the low HSP90a
group (M¼ 43.3, CI 31.6–55.0, P¼ 0.01; Figure 1).
Discussion
In this study, we found a significant association
between higher plasma HSP90a levels and more
severe fatigue in patients with newly diagnosed
Crohn’s disease. These results were consistent in both
correlation and regression analyses. In addition,
HSP90a was the strongest influencing factor for fatigue
when correcting for multiple independent variables.
Patients with the highest HSP90a scores also demon-
strated significantly more fatigue in independent
group analyses.
HSPs are generally thought to be essential cellular
defence proteins, which are produced in conditions that
constitute a threat to cellular life, such as inflammation,
toxic compounds, heat and oxidants.11 HSPs down-
regulate innate immune reactions and inflammation
and reduce tissue damage.18 Some previous animal
studies indicate that HSP90 may have a dual role and
increase inflammation in some conditions, while being
protective and down-regulating inflammation in other
conditions.19–21
Fatigue has previously been an overlooked and
ignored phenomenon in IBD but is increasingly recog-
nised as one of the major problems for many patients.
Clinically significant fatigue affects roughly 50% of
patients at the time of diagnosis.3 Although the path-
ophysiological mechanisms and pathways that generate
fatigue are only beginning to be revealed, the strong
and evolutionarily conserved ‘sickness behaviour’
response appears essential in understanding fatigue in
both animals and humans.7,22 Sickness behaviour is a
genetically based unconscious and temporary behav-
iour evoked during states of infection and cellular
damage to increase survival of the individual.22
The behaviour becomes persistent in states of chronic
inflammation or chronic cellular stress. Crohn’s disease
is a chronic inflammatory condition and therefore trig-
gers this behavioural response in which fatigue is a
major element.
IL-1b has been associated with fatigue in both pre-
clinical and clinical studies, supporting the innate
immune system being fundamentally involved in the
development of sickness behaviour.8,10 Sickness behav-
iour is a well-known cerebral phenomenon.23 A leading
hypothesis is that inflammatory conditions in peripher-
al tissues trigger the release of signal molecules that are
transported into the brain, passing the blood–brain
barrier and binding to specific cellular receptors.7
This can include pro-inflammatory cytokines, such as
IL-1b, but also other molecules that bind to TLR4 on
microglia and lead to intracerebral production of
IL-1b, consequently leading to the generation of sick-
ness behaviour, including fatigue.24
A recent study from our group demonstrated that
fatigue is associated with high levels of HSP90a in pri-
mary Sj€ogren’s syndrome.4 In the current study,
we demonstrated similar findings in Crohn’s disease.
Our findings fit with the hypothesis that HSP90a is
transported into the brain, although the exact mecha-
nism is currently not known. Intracerebrally, HSP90a
may act as a signal molecule for fatigue, possibly
through the TLR4–IL-1b pathway.
Table 3. Multivariable regression model in 53 patients with
Crohn’s disease using fVAS scores as the dependent variable
(r2¼ 0.20, P¼ 0.06).
fVAS
b P value
Age -0.22 0.11
Sex -0.19 0.17
SES-CD -0.07 0.69
CRP (mg/l) 0.14 0.44
HSP90a (ng/ml) 0.35 0.04
fVAS: fatigue visual analogue scale; HSP: heat-shock protein HBI: Harvey
Bradshaw Index; CRP: C-reactive protein; SES-CD: Simple Endoscopic
Score for Crohn’s Disease.
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Figure 1. Fatigue visual analogue scale (fVAS) scores (mm) for
the 20 patients with the highest heat-shock protein 90a
(HSP90a) concentrations (ng/ml) versus the 20 patients with the
lowest HSP90a concentrations. Data are presented as means
with 95% confidence intervals.
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Our findings also support the role of HSP90a as a
fundamentally protective molecule not only for cellular
life, but also by inducing the protective behaviour of
the individual. As such, HSP90a is a ‘super-defence’
protein, providing protection for the organism on
both the micro- and the macro-biological level by
increasing its possibility of surviving.
A generic, validated fatigue instrument, the fVAS,
was used in the current study, allowing comparisons
with other diseases. We previously demonstrated that
HSP90a may be a biomarker of Crohn’s disease activ-
ity.25 Thus, we included selected objective markers of
disease activity and inflammation in our multivariable
analysis. However, HSP90a was still the strongest con-
tributor to fatigue.
We also included newly diagnosed and untreated
patients in the current study, thus avoiding possible
interference from medical treatment, such as cortico-
steroids, on fatigue severity.26
This study has limitations. We did not analyse
HSP90a concentrations in the intestinal mucosa,
the target tissue for inflammation in Crohn’s disease.
We do not have any follow-up data demonstrating
whether the association between HSP90a and fVAS
persists over time. All patients were newly diagnosed
with active disease, so we could not assess if HSP90a
were associated with the presence/absence of disease
activity. In addition, we did not take into account
some other factors that may contribute to fatigue,
such as sleep quality, depression and anxiety.26
In conclusion, high HSP90a plasma levels are
associated with more severe fatigue in Crohn’s disease,
indicating that this protein may be a modulator of
fatigue, possibly acting through intracerebral signalling
pathways. HSP90a inhibitors should be tested in
chronic inflammatory/IBD animal models as a novel
treatment to attenuate sickness behaviour and fatigue.
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